Pfizer Inc. (PFE)
The Zacks Analyst Blog Meta, Pfizer, Salesforce and Smith-Midland
Meta ramps AI infrastructure spending as upgraded recommendations and advertiser tools boost engagement and ad efficiency.
Can Pfizer Achieve High Single-Digit Revenue CAGR From 2029?
PFE targets high single-digit revenue CAGR from 2029 as new launches, acquisitions and pipeline growth may offset LOE headwinds.
Pfizer: Don't Pass On This Dirt-Cheap Buying Opportunity
Pfizer remains materially undervalued, trading at a 9.1x forward earnings multiple and offering a compelling 6.7% dividend yield. LOE headwinds are moderating, with management now expecting $14–15 billion in losses, below prior peak estimates, easing long-term revenue concerns. Execution on recently launched and acquired products is strong, with 22% operational growth and a robust pipeline, particularly in oncology and weight loss.
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
Is Most-Watched Stock Pfizer Inc. (PFE) Worth Betting on Now?
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Pfizer vs Eli Lilly: Different Bets on Pharma M&A
Pfizer (NYSE: PFE | PFE Price Prediction) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma.
Pfizer Beats on Q1 Earnings, New & Acquired Drugs Drive Sales Growth
Pfizer beats Q1 estimates as new launches and acquired drugs lift sales, offsetting COVID declines, while the drugmaker reaffirms its 2026 outlook.
Pfizer beats Q1 revenue and profit estimates, reaffirms 2026 guidance
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported first-quarter 2026 revenue and adjusted profit above Wall Street expectations on Tuesday, driven by strong growth in its launched and acquired products, as the drugmaker reaffirmed its full-year financial outlook. The pharmaceutical giant posted revenue of $14.5 billion for the quarter ended March 31, up 5% from a year earlier and ahead of analyst estimates of $13.84 billion.
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Pfizer (PFE) Q1 Earnings and Revenues Top Estimates
Pfizer (PFE) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.92 per share a year ago.
Pfizer Posts Better-Than-Expected Revenue, Profit
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending.
